Results 101 to 110 of about 45,703 (244)
The conformation of the HIV-1 envelope glycoprotein (Env) substantially impacts antibody recognition and antibody-dependent cellular cytotoxicity (ADCC) responses.
Jonathan Richard +14 more
doaj +1 more source
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core +2 more sources
T‐Cell Immunity and Lung Cancer
ABSTRACT Lung cancer remains a leading cause of cancer mortality worldwide. Although immune checkpoint inhibitors (ICIs) have reshaped therapeutic strategies in lung cancer, their benefits remain limited. ICIs exert their therapeutic efficacy by activating T‐cell effector functions, underscoring the central role of T cells in antitumor immunity.
Kotaro Yamada, Yosuke Togashi
wiley +1 more source
Recent Advances in Bioconjugation of Aromatic Amino Acid Residues by a Reactivity‐Guided Approach
This review highlights recent advances in the bioconjugation of aromatic amino acids residues, focusing on strategies that leverage their inherent chemical reactivity to enable precise and versatile modifications of biomacromolecules, illustrating relevant applications.
Bruno M. da S. Santos +3 more
wiley +1 more source
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh +7 more
wiley +1 more source
Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. [PDF]
Approximately 15-40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS ...
Chen, Irvin SY +17 more
core
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller +16 more
wiley +1 more source
A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models
We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa +16 more
wiley +1 more source
The protective efficacy of human immunodeficiency virus-1 (HIV-1) antibodies (Abs) remains mostly correlated with their in vitro neutralizing activity engaging their Fab region.
Maxence Duchemin +14 more
doaj +1 more source
As the breakthrough bispecific antibody targeting EGFR and c‐Met, EMB‐01 drives potent anti‐tumor efficacy by co‐degradation of both receptors. ABSTRACT The bispecific antibody EMB‐01 (bafisontamab), constructed using EpimAb's proprietary FIT‐Ig platform, is designed to simultaneously target epidermal growth factor receptor (EGFR) and receptor tyrosine
Jing Gao +9 more
wiley +1 more source

